Norwich, New York – January 17, 2013 – Norwich Pharmaceuticals, a provider of full-service
contract development and manufacturing services for the pharmaceutical and biotech industry today
announced that Kristin Arnold, Ph.D. has joined the company as vice president, product development
and technical services (PDTS). Arnold will provide strategic leadership for Norwich’s PDTS group that
includes R&D, GMP pilot scale manufacturing, analytical development and validation, and testing
services. Arnold will report to Chief Executive Officer Doug Drysdale.
"We are pleased to welcome Kristin Arnold to Norwich and look forward to her contributions to the
PDTS group and the organization," stated Drysdale. "Her expertise in product development from
product conception through market launch will be an advantage for our customers and she will be a
strong addition to our leadership team."
Prior to joining Norwich, Dr. Arnold worked for organizations including URL Pharma as Sr. Vice
President Product Development, Alpharma (formerly Faulding Pharmaceutical Company) as Sr.
Director Research and Development, FMC Corporation, Ecogen, and Monsanto.
Dr. Arnold holds a Bachelor of Science in chemistry from LaSalle University and a Ph.D. in organic
chemistry from the University of Miami. She is a member of both the American Chemical Society and
the American Association of Pharmaceutical Scientists. With more than twenty publications in
scientific journals, Dr. Arnold holds four US patents and has over ten patent publications.
About Norwich Pharmaceuticals
Norwich is a full-service contract development and manufacturing provider for Rx and OTC
pharmaceuticals. Norwich applies more than 125 years of experience and an unparalleled compliance
record to offer customers greater flexibility, resources and speed that result in a streamlined
progression from product development to scale-up and commercial manufacturing through clinical
services. Visit www.norwichpharma.com for additional information.